Prostate cancer is still one of the leading causes of death in men of developed countries including the U. S., despite of the recent progress in its diagnosis and treatment. Although the advanced tumors initially respond to therapies such as androgen ablation, anti-androgen or the taxane-based chemotherapy, most of them develop resistance and the disease relapses. Therefore, there is an urgent need for better understanding of the resistance mechanisms and to identify markers and therapeutic targets for personalized treatment and improving survival. Current evidence supports the notion that multiple diverse pathways and mechanisms drive tumor resistance to different therapies including chemoresistance. Therefore, it will be highly significant if key resistance driving factors that interface the seemingly complex arrays of pathways can be identified. This proposal is based on our recent identification of an epigenetic regulator/histone methylase protein as a key factor of prostate cancer cell survival, proliferation and tumor growth. It functions as a novel co-activator of AR and NF-kB for induction of cell survival, pro-inflammatory gene and kinase signaling programs. Interestingly, it is induced by chemotherapeutic drugs and is overexpressed in prostate cancer tumors with high Gleason scores. Here, we wish to establish its function in driving chemoresistance and elucidate its functional mechanism as a key activator of multiple pathways involved in therapeutic resistance. We will also examine the epigenetic regulator for the potential value as a prognostic marker and a therapeutic target.

Public Health Relevance

Prostate cancer represents the most commonly diagnosed non-cutaneous malignancy among the veterans in the U. S. It is still one of the leading causes of cancer-related death in men. Although the advanced prostate cancers initially respond to the different therapies including the taxane-based chemotherapy, most of them develop resistance and the disease relapses. Therefore, there is an urgent need for better understanding of the resistance mechanisms and to identify markers and therapeutic targets for personalized treatment and improving survival. We propose to identify a novel protein with enzymatic activity as one of the key players in driving therapeutic resistance. Through elucidation of its functional mode, we wish to establish its value as a novel prognostic marker and a therapeutic target for successfully blocking the disease progression.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
1I01BX002237-01
Application #
8540889
Study Section
Oncology A (ONCA)
Project Start
2014-04-01
Project End
2018-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
VA Northern California Health Care System
Department
Type
DUNS #
127349889
City
Mather
State
CA
Country
United States
Zip Code
95655